Fig. 6

MOMIPP and a PIKfyve inhibitor, YM201636, have different effects on the JNK pathway and glucose uptake. a U251 cells were treated for 4 h with 10 μM MOMIPP or YM201636 and cell morphology was observed by phase-contrast microscopy. b CellTiterGlo® viability assays were carried out on U251 cells treated with the indicated concentrations of MOMIPP or YM201636 for 48 h (n = 3 for each concentration). The decreases in ATP in the cultures treated with both drugs at concentrations of 2.5, 5 and 10 μM (compared to controls without drug) were significant at p ≤ 0.05. c, d U251 cells were treated for 24 h with the indicated concentrations of MOMIPP or YM2011636, and aliquots of cell lysate containing equal amounts of protein were then subjected to immunoblot analysis for phospho- and total JNK1/2 and c-Jun (c), or phospho- and total Bcl-2 and Bcl-xL (d). The blots are representative of similar results obtained in three separate experiments. e [³H]2-DG uptake was assayed in U251 cells after a 24 h exposure to 10 μM MOMIPP or YM201636, with the results expressed as percent of the parallel DMSO controls (mean ± SD, n = 3). Asterisks indicate that decreases were statistically significant compared to the controls (p ≤ 0.05)